ArticleExperimental and therapeutic medicine2022
MUC21 induces the viability and migration of glioblastoma via the STAT3/AKT pathway.
Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Transmembrane mucin 21 drives lung adenocarcinoma growth by suppressing retinoic acid receptor β signaling.Journal of thoracic disease · 2026Article
- MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis.Frontiers in oncology · 2026Article
- Thioflavin T Lasing Probe for Mucin Detection in Simulated Tears as a Targeting Strategy for Brain Tumors.ACS chemical neuroscience · 2025Article
- Mucins as Precision Biomarkers in Glioma: Emerging Evidence for Their Potential in Biospecimen Analysis and Outcome Prediction.Biomedicines · 2024Review
- GDNF-induced phosphorylation of MUC21 promotes pancreatic cancer perineural invasion and metastasis by activating RAC2 GTPase.Oncogene · 2024Article
- MUC21: a new target for tumor treatment.Frontiers in oncology · 2024Review
- A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity.Journal of experimental & clinical cancer research : CR · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is a malignant tumor with one of the fastest increasing morbidity and mortality rates. As such, more therapeutic targets need to be developed to combat this disease. Mucin 21 (MUC21) is a human counterpart of mouse epiglycanin and mediates multiple cellular functions. However, its possible effects on GBM and its possible mechanism remain unclear. The current study aimed to clarify the role or MUC21 in the progression of GBM by performing a series of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.